Lisinopril HCTZ

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-23-D-0005

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Hauppauge, New York, UNITED STATES

SourceSAM
Documents3
This procurement notice announces the award of a national contract (SPE2D2-23-D-0005) for the supply of Lisinopril HCTZ tablets, a pharmaceutical product used primarily in the management of hypertension. The contract is managed by the Defense Logistics Agency (DLA) Troop Support, a federal office responsible for ensuring the availability of critical medical and pharmaceutical supplies to military and federal entities. The scope of this contract encompasses the manufacturing and delivery of Lisinopril HCTZ tablets, aligning with NAICS code 325412 (Pharmaceutical Preparation Manufacturing). The place of performance is specified as Hauppauge, New York, indicating that manufacturing, distribution, or fulfillment activities will be centered in this location. The contract falls under Product Service Code 6505, which covers drugs and biologicals, further emphasizing the pharmaceutical nature of the requirement. The intended outcome of this procurement is to secure a reliable and consistent supply of Lisinopril HCTZ tablets to meet the ongoing needs of federal customers, ensuring continuity of care and readiness. Contractors are expected to adhere to stringent quality standards typical of pharmaceutical manufacturing, with all deliverables conforming to applicable federal regulations and industry best practices. DLA Troop Support serves as the contracting entity, providing oversight and contract administration. Interested parties or current contractors may direct inquiries to the primary contact, Ryan Ferry ([email protected], 215-737-3182), or the secondary contact, Jason Wray ([email protected], 215-737-0614), for further information or clarification regarding contract requirements. This award notice is currently active and was posted on September 1, 2024. Additional details, including attachments relevant to the contract, can be accessed via the official SAM.gov opportunity listing (https://sam.gov/opp/61435dfee7614ad3aab0437f70868c07/view). Contractors evaluating this opportunity should note that the contract is national in scope, with a focus on pharmaceutical manufacturing and supply, and is administered by a federal defense logistics agency. No specific set-aside requirements or special considerations are indicated in the notice. This opportunity is best suited for established pharmaceutical manufacturers with the capability to produce and deliver Lisinopril HCTZ tablets in compliance with federal standards, and who can support the logistical and quality assurance demands of a national-level contract.